Erik Roy Hillesland v. Glenmark Pharmaceuticals, Inc. USA

• Court: Court of Appeals for the Eleventh Circuit
• Decided: February 23, 2024
• Docket: 23-14181
• Status: Unpublished

Opinion

USCA11 Case: 23-14181 Document: 8-1 Date Filed: 02/23/2024 Page: 1 of 2

[DO NOT PUBLISH] In the United States Court of Appeals For the Eleventh Circuit ____________________

No. 23-14181 Non-Argument Calendar ____________________

IN RE: ZANTAC (RANITIDINE) PRODUCTS LIABILITY LITIGATION ___________________________________________________ 9:20-md-02924-RLR ERIK ROY HILLESLAND, Interested Party-Appellant, versus GLENMARK PHARMACEUTICALS, INC. USA, APOTEX CORP., MICHAEL MCCANDLESS, BRAD ALDRIDGE, AJANTA PHARMA USA, INC., et al., Defendants-Appellees. USCA11 Case: 23-14181 Document: 8-1 Date Filed: 02/23/2024 Page: 2 of 2

2 Opinion of the Court 23-14181 ____________________

Appeal from the United States District Court for the Southern District of Florida D.C. Docket No. 9:20-md-02924-RLR ____________________

Before LUCK, BRASHER, and ABUDU, Circuit Judges. PER CURIAM: This appeal is DISMISSED, sua sponte, for lack of jurisdic- tion. As explained in our previous opinion dismissing appeal no. 23-11047, Appellant Erik Hillesland lacks standing to appeal be- cause he did not properly become a plaintiff in this action. See Wolff v. Cash 4 Titles, 351 F.3d 1348, 1353-54 (11th Cir. 2003) (explaining that litigants must establish their standing to appeal, and only a lit- igant who is aggrieved by a judgment or order may appeal); Marino v. Ortiz, 484 U.S. 301, 304 (1988) (noting that in general, only par- ties or those who properly become parties may appeal). No petition for rehearing may be filed unless it complies with the timing and other requirements of 11th Cir. R. 40-3 and all other applicable rules.